These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17662202)

  • 1. [Incretins as new therapeutic targets of type 2 diabetes].
    Puig-Domingo M; Reviriego J
    Rev Clin Esp; 2007; 207(7):352-64. PubMed ID: 17662202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
    Schnabel CA; Wintle M; Kolterman O
    Vasc Health Risk Manag; 2006; 2(1):69-77. PubMed ID: 17319471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretins and their role in the management of diabetes.
    Frias JP; Edelman SV
    Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
    González C; Beruto V; Keller G; Santoro S; Di Girolamo G
    Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL
    Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New drugs; exenatide and sitagliptin].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Apr; 152(15):876-9. PubMed ID: 18512528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Exenatid and its position as antidiabetic drug in the treatment of type 2 diabetes mellitus].
    Perusicová J
    Vnitr Lek; 2008 Apr; 54(4):377-86. PubMed ID: 18630617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide: its position in the treatment of type 2 diabetes.
    Guerci B; Martin CS
    Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin-based therapies: review of current clinical trial data.
    Peters A
    Am J Med; 2010 Mar; 123(3 Suppl):S28-37. PubMed ID: 20206729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
    Briones M; Bajaj M
    Expert Opin Pharmacother; 2006 Jun; 7(8):1055-64. PubMed ID: 16722815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide.
    Barnett AH
    Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.